FDA Notice On Elan's Tysabri Imminent?

More: "[Dow Jones] The FDA could provide Elan (ELN) and Biogen Idec (BIIB) with an advisory panel meeting on their suspended MS drug Tysabri within the next few days, says Davy Stockbrokers, assuming a 45-day notice period. Adds March 7 is the most likely date for an FDA advisory panel meeting"